WO2000032587A1 - Substances sf2809-i, ii, iii, iv, v et vi presentant une activite d'inhibition de la chymase - Google Patents
Substances sf2809-i, ii, iii, iv, v et vi presentant une activite d'inhibition de la chymase Download PDFInfo
- Publication number
- WO2000032587A1 WO2000032587A1 PCT/JP1999/006738 JP9906738W WO0032587A1 WO 2000032587 A1 WO2000032587 A1 WO 2000032587A1 JP 9906738 W JP9906738 W JP 9906738W WO 0032587 A1 WO0032587 A1 WO 0032587A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substance
- formula
- substances
- iii
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to SF2809-I substance, SF2809-II substance, SF2809-111 substance, SF2809-IV substance, SF2809-V substance and SF2809-VI substance, which are novel compounds having chimase inhibitory activity Or its salt.
- the present invention relates to a method for producing the SF2809-I substance to SF2809-VI substance.
- the present invention includes as an active ingredient SF2809-I, —11, —111, _IV, —V, or a pharmaceutically acceptable salt of a substance such as VI.
- the present invention also relates to a pharmaceutical composition and a chimase inhibitor
- the present invention further encompasses a novel microorganism, strain SF2809, having the above-mentioned property of producing the SF2809-I substance to SF2809-VI substance.
- the enzyme chymase is a chymotrypsin-like serine protein that is mainly stored in mast cell granules and secreted into tissues such as heart, blood vessels, and skin.
- One of the main actions of chimase is an action of producing angiotensin 11 using angiotensin I as a substrate.
- angiotensin II is carried out mainly by angiotensin converting enzyme (ACE).
- ACE angiotensin converting enzyme
- the serine protease in the left ventricle of the human heart was sequenced and identified as a chimase with a molecular weight of about 30,000 (Urata et al., J. Biol. Chem., 266, 17173-17179, 1991). It is known that chymase activity is increased in the heart during restenosis progression after vascular injury and cardiomyopathy. Therefore, chimase inhibitors are expected to be used as treatments or prophylaxis for cardiac hypertrophy, heart failure or arteriosclerosis. In addition, chymase is known to promote mast cell degranulation, and it is expected that chymase inhibitors will be useful as anti-inflammatory drugs and anti-allergic drugs. You.
- chimase may also be used for the production of endothelin collagenase, pradikinin, substance P, neurotensin, somato Metabolism of various physiologically active peptides such as statin, VIP, LH-RH, ⁇ -MSH, cells such as collagen, fibronectin, and vitronectin Limited degradation of outer matrix, degradation of blood clotting factors such as trombin, antiproliferative secretion of airway mucosal glands, and foaming of the mouth phage It is known to have effects such as promotion. Chimase inhibitors treat asthma, rheumatism, thrombosis or bronchitis, etc. Is also expected to be useful.
- peptide-type chimase inhibitors are disclosed in International Patent Application Publications W093 / 25574, W095 / 27053, and W095 / 27055. You. On the other hand, non-peptide chimase inhibitors have been disclosed in International Patent Application Publication Nos. WO096 / 04248 and JP-A-Patent Publication No. 713876, and the chimerase in the form of a microbial product has been disclosed. Japanese Patent Application Laid-Open No. 10-101666 discloses an inhibitor.
- An object of the present invention is to provide a novel compound having an excellent enzyme inhibitory activity against chymase.
- Another object of the present invention is to provide a method for producing a novel chymase inhibitory active compound. Still another object of the present invention is to provide a novel pharmaceutical composition having a chimase inhibitory activity, which is useful as a medicament, and a chymase inhibitor. . Disclosure of invention
- the present inventors have conducted various studies. As part of that research, the present inventors searched for new compounds using microbial products as a source in order to discover and develop novel compounds having chymase inhibitory activity. Was performed. The present inventors also concluded that Mikuguchi Mono, a novel microorganism isolated from a soil sample collected from Hachijojima, Tokyo and named SF2809 strain. One strain of Sporidae was cultured. As a result, it was found that the human chymase inhibitory activity was expressed in the culture of this SF2809 strain. Furthermore, as a result of the research, six types of active substances having human chymase inhibitory activity were successfully isolated and purified from the culture ability of the SF2809 strain.
- each of these six active substances has a chemical structure represented by the following formulas (I) to (IV).
- Each of these six active compounds was confirmed to be a novel compound.
- These substances were named SF2809-I, SF2809-II, SF2809-111, SF2809-IV, SF2809-V, and SF2809-VI, respectively.
- SF2809-I substance represented by the formula (I) described below SF2809-II substance represented by the formula (II), SF2809-III substance represented by the formula (III),
- the SF2809-IV substance represented by the formula (IV), the SF2809-V substance represented by the formula (V), and the SF2809-VI substance represented by the formula (VI) are: It was confirmed that the enzyme had an activity of inhibiting chitinase. Then, it was recognized that these SF 2809-I substances to -VI substances can be generally represented by the following general formula (VII). Based on these findings, the present invention has been completed.
- R 1 is a hydrogen atom, a phenyl group or a p-hydroxyphenyl group, and R 2 is an acetylamino group-NHC0CH 3 or hydrogen It is a xylene group, and in SF2809-I substance, R 1 is a hydrogen atom and! ⁇ Is an acetinole amino group, in the SF2809-11 substance, R 1 is a P-hydroxyphenyl group and R 2 is an acetylamino group, and SF2809-111 substance
- R 1 is a hydrogen atom and R 2 is a hydroxy group.
- R 1 is a P-hydroxy phenyl group and R 2 is a hydroxy group.
- R 1 is a phenyl group and IT is an acetylamino group
- R 1 is a phenyl group and R 2 is a phenyl group.
- the following formula (I) Provided is a SF2809-I substance represented by the formula: or a pharmaceutically acceptable salt thereof.
- SF2809-II substance represented by or a pharmaceutically acceptable salt thereof.
- SF2809-III substance represented by the formula: or a pharmaceutically acceptable salt thereof.
- SF2809-IV substance represented by the formula: or a pharmaceutically acceptable salt thereof.
- SF2809-V substance represented by the formula: or a pharmaceutically acceptable salt thereof.
- SF2809-I, SF2809-II, SF2809-III, SF2809-IV, SF2809-V and SF2809-VI represented by the above formulas (I) to (VI), respectively Acceptable salts include alkaline metal salts, such as sodium and potassium, or alkaline earth metal salts, such as canoleum and rubber. And acid addition salts with pharmaceutically acceptable inorganic acids, organic acids and the like.
- R 1 is a hydrogen atom, a phenyl group or ⁇ -hydroxy.
- R 2 is an acetylamino group—NHC0CH 3 or a hydroxy group.
- the SF2809-I substance is represented by the above formula (I) and has the following physicochemical properties.
- Solubility Soluble in methanol, ethyl acetate and dimethyl sulfoxide, hardly soluble in porcine mouth, and insoluble in hexane and water It is.
- the first SF2809-II substance according to the present invention is represented by the above formula (II) and has the following physicochemical properties.
- Solubility Soluble in methanol, ethyl acetate and dimethyl sulfoxide, poorly soluble in cross-linked form, and insoluble in hexane and water. .
- the first SF2809-III substance according to the present invention is represented by the above formula (III), and has the following physicochemical properties.
- V raax KBr cm -1 1628, 1608, 1576, 1460, 1336, 1236,
- Solubility Soluble in methanol, ethyl acetate and dimethyl sulfate, hardly soluble in chloroform, and insoluble in hexane and water It is.
- the first SF2809-IV substance according to the present invention is represented by the above formula (IV) and has the following physicochemical properties.
- Solubility Soluble in methanol, ethyl acetate and dimethylsolefoxide, hardly soluble in chlorophenol, and helium Insoluble in san and water.
- the first SF2809-V substance according to the present invention is represented by the above formula and has the following physicochemical properties.
- V max KBr cm— 1 1632, 1611, 1589, 1572, 1460, 1387,
- Solubility Soluble in methanol, ethyl acetate, dimethyl phenol phenol, and phenol phenol, and insoluble in hexane and water.
- the first SF2809-VI substance according to the present invention is represented by the above formula (VI) and has the following physicochemical properties.
- V maY KBr cm— 1 1624, 1610, 1589, 1574, 1460, 1395,
- Solubility Soluble in methanol, ethyl acetate, dimethyl sulfoxide and chlorophoronelem, and insoluble in hexane and water.
- a bacterium that produces at least one of the VI substances is cultured, and SF2809-I substance, SF2809-II substance, SF2809_I11 substance, SF2809-IV substance, SF2809- It is characterized by collecting at least one of V substance and SF2809-VI substance, SF2809-1 substance, SF2809-II substance, SF2809-III substance, SF2809-IV substance, SF2809—V substance and (or f) SF2809—VI substance manufacturing method Provided.
- SF2809 The bacteria producing at least one of SF2809-I, -11, -111, -IV, -V, and -VI used in the second method of the present invention are referred to simply as “SF2809” in the following description. Abbreviated as “substance producing bacteria”.
- SF2809 substance-producing bacterium for example, it has been recognized that the present inventors are newly isolated from a soil sample collected in Hachijojima, Tokyo and belong to the family Mikuguchi Monosporaceae.
- Strain SF2809 strain The bacteriological properties of this SF2809 strain are as follows.
- the SF2809 substance producing bacterium used in the method of the present invention is not limited to the specific microorganism described in this specification.
- SF2809 A substance that has the ability to produce at least 3 of substance I to VI substance may be used as an SF2809 substance producing bacterium.
- microorganisms that can be used include SF2809 strain, or subcultures of these strains, artificial mutants, natural mutants, and the like.
- the medium and methods used for observing the morphology, culture characteristics, and physiological properties of the SF2809 strain were mainly based on Charling and Gottve (Shrling, EB and Gottlieb, D., Int. J. Syst. Bacterid., Vol. 16, pp. 313-340, 1966) and Waxman (SA, The actinoraycetes Vol. 2: Classification, identification and description of genera and speci es. The Wi ll iams and Wikins Co., Baltimore, 1961).
- this strain was used in ISP medium, yeast ex./starch agar medium (yeast ex. 0.2%, starch 1.0%, agar 18g, purified water 1L, H7.
- the vegetative mycelium of strain SF2809 (0.4-0.5 ⁇ m in diameter) develops well and branches irregularly, but does not rupture. No formation of aerial hyphae is observed.
- a large number of spherical spore-like structures are formed alone in the vegetative hypha. They have a diameter of 1.0-1.6 / m and have a smooth or slightly rough surface.
- the culture and physiological properties of the SF2809 strain are shown in Tables 1 and 2 below, and the availability of carbon sources is shown in Table 3. Growth was normal to poor in many media, and globular spore-like structures were observed in all media. The color of the vegetative mycelium is orange-orange-brown. Blackening of the colony and humidification during ripening observed in typical Micromonospora are observed in the SF2809 strain. Can't
- Major bacterial fatty acids are branched fatty acids of iso-C16: 0, iso-C15: 0, anteiso-C17: 0, anteiso-C15: 0, iso-C17: 0, and occupy about 80%.
- mono-unsaturated branched fatty acids and linear saturated fatty acids each contain 5 to 10%, and do not contain 10-methyl fatty acids or hydroxy fatty acids.
- the SF2809 strain has abundantly formed spherical structures, which are spherical structures that are often formed by bacteria of the genus Dactylosbolangium. Is similar to a global 'body'.
- Ensign et al. It has been shown that globos bodies germinate, and it is clearly revealed that they are a kind of seeds. (Ensign, J.C., Ann. Rev. Microbiol, 32, 185-219, 1978) 0
- SF2809 strain is a fungus belonging to the genus Dactylosporang iura, which has lost the ability to form asci. Research is ongoing to determine if the SF2809 strain can be determined to be a fungus of the genus Dactylosporangium.
- SF2809 has accession number FERM P on August 31, 1998.
- a SF2809 substance-producing bacterium preferably, for example, the SF2809 strain is cultured in a nutrient medium containing an appropriate carbon source and nitrogen source.
- the medium used may be a natural medium or a synthetic medium.
- Carbon sources include carbohydrates such as glucose, fructose, sucrose, molasses, starch or starch hydrolysate, and acetic acid, propionic acid, etc.
- Organic acids or alcohols such as glycerin are used.
- the nitrogen sources are usually peptone, meat extract, yeast extract, cone cheaper, oatmeal, wheat germ, casein hydrolyzate, Soybean meal and soybean meal hydrolyzate are used, but ammonium salts (for example, ammonium chloride, ammonium sulfate, ammonium nitrate, phosphoric acid, etc.) are used.
- ammonium salts for example, ammonium chloride, ammonium sulfate, ammonium nitrate, phosphoric acid, etc.
- Inorganic and organic nitrogen compounds such as ammonium, urea and amino acids are also effective.
- these carbon sources and nitrogen sources can be used in combination.
- potassium phosphate, potassium phosphate, phosphate, phosphate Magnesium, magnesium sulphate, sodium chloride, ferrous sulphate, manganese sulphate, copper sulphate, calcium sulphate or other inorganic salts It may be added to the medium.
- the culture medium foams, liquid paraffin, animal oil, vegetable oil, mineral oil, silicon, or the like can be added.
- Culture of the SF2809 substance-producing bacterium is performed under aerobic conditions by shaking culture or deep-aeration stirring culture. The culture temperature is SF
- 2809 substance-producing bacteria is Ru cormorants appropriately changed within the range you produce eye substances force s, and rather is 15 ⁇ 37 ° C is not good preferred.
- the culturing time is usually 1 to 10 days. After completion of the culture, the culture or et purpose substances der Ru SF2809 c (2) of least for the even purified et al or were taken One of substance SF2809 substance collecting purified
- the culture is first separated into bacteria and a culture filtrate by filtration or centrifugation.
- appropriate combination of ordinary separation means utilizing the properties of SF2809 substance for example, solvent extraction method, adsorption / desorption method using adsorbent, chromatographic method using various resins, precipitation method, etc.
- the SF2809 material can be separated and further purified. For example, acetonitrile is added to the culture of the SF2809 strain to extract the SF2809 substance from the cell viability and then filtered. Further, after the acetone is distilled off from the filtrate, extraction is performed with ethyl acetate.
- each of the SF2809-I substance to SF2809-VI substance according to the first present invention has an inhibitory activity against chymase.
- the chymase inhibitory activity of SF2809 substance was determined according to the following test example. Examined.
- Test Example 1 the chymase inhibitory activity of SF2809 substance was measured as follows.
- the recombinant pro-type human kinase used was prepared according to the report of Urata et al. (Urata et al., J. Biol. Chem., 266, 17173, 1991). That is, an insect cell (Tn5) infected with a recombinant baculovirus containing a cDNA encoding human chimase is cultured, and the culture supernatant is obtained. Chimase was collected and purified from Parincose Rose (Pharmacia). In addition, a report by Neo-Kami et al. (Murakami et al., J. Biol. Chem., 270, 2218, 1991). After activation of a purified requimase purification log, heparin separation was performed. Purification was performed on a rose to obtain an activated human liver.
- SF2809-I substance, -II substance, -III substance, -IV substance, -V substance and -VI substance required to inhibit the enzymatic activity of the above-mentioned human liver enzyme by 50%.
- IC 5 () values substances respectively, 7.3 X 10- 6 M, 4. 1 X 10-. M, 2. 1 X 10- 6 M , 8. 1 X 10- U M, 4. is and this Ru 3 X 10 _8 M your good beauty 1.4 X 10 _8 M der was admitted et al.
- SF2809-I, SF2809-II, SF2809-III, SF2809-IV, SF2809-V and SF2809-VI all have a chimase inhibitory activity.
- these SF2809-I substances to SF2809-VI substances make use of chymase inhibitory activity, for example, myocardial infarction, cardiac hypertrophy, heart failure, cardiomyopathy, arteriosclerosis, hypertension, intimal hyperplasia It is useful for the treatment or prevention of peripheral circulatory disorders, renal failure, allergies, various inflammations, atopic dermatitis, rheumatism, asthma, and bronchitis.
- Each substance of SF2809 according to the present invention can be mixed with a conventional pharmaceutically acceptable solid or liquid carrier to prepare a pharmaceutical composition.
- the SF2809-I substance, SF2809-II substance, SF2809-III substance, SF2809-IV substance, SF2809-V substance or SF2809-VI substance ⁇ Maso Pharmacy
- the present invention provides a pharmaceutical composition comprising a commercially acceptable salt together with a pharmaceutically acceptable carrier.
- the third composition of the present invention has a chimase inhibitory activity and can be administered as a medicine to animals including humans.
- the third composition of the present invention is used for myocardial infarction, cardiac hypertrophy, heart failure, cardiomyopathy, arteriosclerosis, hypertension, intimal hyperplasia, peripheral circulatory disorders, renal failure, allergy, various inflammations, It is effective in treating or preventing pea dermatitis, rheumatism, asthma, bronchitis, etc.
- the compounded carrier can be a solid or liquid carrier commonly used in pharmaceutical technology.
- the solid carrier can be, for example, starch, lactose, crystalline cellulose, calcium carbonate, and the liquid carrier can be, for example, saline, aqueous ethanol. It can be a rule or an ethanol.
- the content of the SF 2809 substance as an active ingredient in the present composition is not particularly limited as long as it is an amount sufficient to treat a disease, but, for example, the weight of the entire composition
- the range can be from 0.01% to less than 100%, and preferably from 0.1% to 80%, based on the
- Formulations for oral administration include tablets, pills, granules, capsules, powders, solutions, suspensions, syrups, and sublinguals And the like.
- Formulations for parenteral administration include injections, transdermal absorption agents, inhalants, suppositories and the like.
- pharmaceutical additives such as surfactants, excipients, stabilizers, wetting agents, disintegrants, solubilizing agents, isotonic agents, buffers, coloring agents, flavoring agents and the like are used. Use as appropriate.
- SF2809-I to SF2809-VI as a medicament varies depending on the age, weight, type and degree of disease, and route of administration of the substance, but is considered to be orally administered to humans. to c is found to be administered within the same rather 0.
- the SF2809-I substance of the formula (I), the SF2809-II substance of the formula (II), the SF2809-III substance of the formula (111), and the SF2809-IV of the formula (IV) A chymase inhibitor comprising a substance, a SF2809-V substance of the formula (V) or a SF2809-VI substance of the formula (VI), or a pharmaceutically acceptable salt thereof is provided.
- each of SF2809-I substance to SF2809-VI substance or a salt thereof can be used alone as it is, for example, for an enzyme. Can be used as a reagent.
- useful and novel microorganisms are microorganisms having the above-mentioned mycological properties and belonging to the genus Dactylorchia sporangium. Therefore, the SF2809-I substance of the formula (I), the SF2809-11 substance of the formula (II), the SF2809-III substance of the formula (III), the SF2809-IV substance of the formula (IV), and the formula (V) To produce SF2809-V substance and SF2809-VI substance of formula (VI) Yes, and SF2809 shareholding S with the accession number of F ERM BP 6872 from the Institute of Biotechnology and Industrial Technology, AIST. BEST MODE FOR CARRYING OUT THE INVENTION
- Glucose 1.0%, soluble starch 2.0%, yeast extract 0.3% polypeptone 0.5%, wheat germ 0.6%, soybean meal 0.2% and carbon dioxide Dispense 20 ml of pre-culture medium containing 0.2% of shim and adjusted to pH 7.0 with 6N NaOH into three 100 ml Ellenmeyer flasks and sterilize at 120 ° C for 20 minutes. did.
- a platinum loop of the SF2809 strain (deposited as FERM BP-6872) cultured on an agar plate was inoculated onto the plate, and cultured with shaking at 28 ° C for 4 days.
- 120 L of the culture thus obtained was separated into bacterial cells and supernatant by centrifugal filtration.
- 100 L of ethyl acetate was added to the supernatant and extracted with stirring.
- 50 L of 50% acetone was added to the cells by extraction, and the acetone was distilled off from the filtrate under reduced pressure, followed by extraction with 30 L of ethyl acetate.
- the thus obtained ethyl acetate layers were combined and concentrated under reduced pressure to obtain a crude extract (56 g).
- the crude extract was washed with 2 L of hexane, dissolved in 500 ml of methanol, added with 150 g of silica gel ((CO-GEL C300, Wako Pure Chemical Industries) and dried under reduced pressure. Hardened.
- the crude extract thus adsorbed on silica gel is layered on 300 g of silica gel on a glass filter, washed with 3 L of chlorophore / rem, and washed with 3%
- the active fraction was eluted with methanol, and the active fraction was collected and dried (1.9 g).
- the obtained residue was dissolved in a small amount of methanol, and twice the volume of water was added.After that, the obtained solution was filled with 30% acetonitrile / water.
- Cosmo cinnamon 300 ml, Nakaraitesk Overlaid on the column.
- the active fraction was eluted initially with 30% acetonitrile and then with 70% acetonitrile, and the active fraction was collected and dried (107 mg).
- the active fraction obtained was dissolved in a small amount of methanol, and the solution was divided into three portions and subjected to HPLC (column: inert solvent 0DS-2, inner diameter 2 cm x 25 cm) , JEOL Resin Sciences Co., Ltd.) and eluted with a gradient of 40% to 65% acetonitrile / water. Six fractions were obtained as active fractions. These 6 fractions were each dried. Thus, SF2809-I (2.3 mg) and SF2809-II
- SF2809 1 substance, SF2809-II substance, SF2809-III substance, SF2809-IV substance, SF2809-V substance and SF2809-VI substance having chimase inhibitory activity are provided.
- the substances or their pharmaceutically acceptable salts were obtained.
- a method for producing SF2809-I-VI substances are also provided.
- the SF2809-I to -VI substances according to the present invention are expected to be effective for the treatment or prevention of various diseases involving Chimazeca S,
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU14140/00A AU1414000A (en) | 1998-12-01 | 1999-12-01 | Sf2809-i, ii, iii, iv, v and vi substances exhibiting chymase-inhibiting activities |
US09/857,037 US6432978B1 (en) | 1998-12-01 | 1999-12-01 | SF2809-I,II,III,IV,V and VI substances exhibiting chymase-inhibiting activities |
EP99973023A EP1136488A4 (en) | 1998-12-01 | 1999-12-01 | SF2809-I, II, III. VI, V AND VI COMPOUNDS WITH CHYMASE INHIBITING EFFECT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10/341523 | 1998-12-01 | ||
JP34152398 | 1998-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000032587A1 true WO2000032587A1 (fr) | 2000-06-08 |
Family
ID=18346733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/006738 WO2000032587A1 (fr) | 1998-12-01 | 1999-12-01 | Substances sf2809-i, ii, iii, iv, v et vi presentant une activite d'inhibition de la chymase |
Country Status (4)
Country | Link |
---|---|
US (1) | US6432978B1 (ja) |
EP (1) | EP1136488A4 (ja) |
AU (1) | AU1414000A (ja) |
WO (1) | WO2000032587A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001083471A1 (fr) * | 2000-05-02 | 2001-11-08 | Meiji Seika Kaisha, Ltd. | Nouveaux derives indoliques presentant des activites inhibitrices de chymase et leur procede de preparation |
US6921766B1 (en) * | 1999-11-01 | 2005-07-26 | Daiichi Suntory Pharma Co., Ltd. | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor |
JP2010505900A (ja) * | 2006-10-13 | 2010-02-25 | エフ.ホフマン−ラ ロシュ アーゲー | キマーゼ阻害剤としてのビニル酸誘導体 |
JP4824092B2 (ja) * | 2005-12-01 | 2011-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なビニル様酸誘導体 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1520314A (zh) * | 2001-08-24 | 2004-08-11 | 帝人株式会社 | 含有食糜酶抑制剂和ace抑制剂作为有效成分的药物 |
DE10251557A1 (de) * | 2002-11-06 | 2004-05-19 | Robert Bosch Gmbh | Handwerkzeugmaschine mit einem pistolenförmigen Handgriff |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004248A1 (fr) * | 1994-07-29 | 1996-02-15 | Suntory Limited | Derives d'imidazolidine et son utilisation |
JPH08208654A (ja) * | 1994-11-24 | 1996-08-13 | Wakamoto Pharmaceut Co Ltd | キマーゼ活性を阻害し、かつ一酸化窒素生成を抑制する新規トリアジン誘導体 |
JPH10101666A (ja) * | 1996-10-02 | 1998-04-21 | Shionogi & Co Ltd | 新規ベンゾオキサシクロトリデシン化合物およびそれを含有する医薬組成物 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5268378A (en) * | 1990-05-31 | 1993-12-07 | Merck Sharp & Dohme, Limited | Dioxo-tetrahydroquinoline derivatives |
WO1993025574A1 (en) * | 1992-06-12 | 1993-12-23 | Pfizer Inc. | Inhibitors of angiotensin i chymase(s) including human heart chymase |
DE69622148T2 (de) * | 1995-09-28 | 2002-10-31 | Suntory Ltd Osaka | Chinazozin derivate und deren verwendung |
-
1999
- 1999-12-01 EP EP99973023A patent/EP1136488A4/en not_active Withdrawn
- 1999-12-01 WO PCT/JP1999/006738 patent/WO2000032587A1/ja not_active Application Discontinuation
- 1999-12-01 AU AU14140/00A patent/AU1414000A/en not_active Abandoned
- 1999-12-01 US US09/857,037 patent/US6432978B1/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004248A1 (fr) * | 1994-07-29 | 1996-02-15 | Suntory Limited | Derives d'imidazolidine et son utilisation |
JPH08208654A (ja) * | 1994-11-24 | 1996-08-13 | Wakamoto Pharmaceut Co Ltd | キマーゼ活性を阻害し、かつ一酸化窒素生成を抑制する新規トリアジン誘導体 |
JPH10101666A (ja) * | 1996-10-02 | 1998-04-21 | Shionogi & Co Ltd | 新規ベンゾオキサシクロトリデシン化合物およびそれを含有する医薬組成物 |
Non-Patent Citations (2)
Title |
---|
FUKAMI H. ET AL.: "Chymase: its pathophysiological roles and inhibitors", CURR. PHARM. DES.,, vol. 4, no. 6, December 1998 (1998-12-01), pages 439 - 453, XP002926098 * |
See also references of EP1136488A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6921766B1 (en) * | 1999-11-01 | 2005-07-26 | Daiichi Suntory Pharma Co., Ltd. | Blood vessel lipid deposition-preventive agent comprising chymase-inhibitor |
WO2001083471A1 (fr) * | 2000-05-02 | 2001-11-08 | Meiji Seika Kaisha, Ltd. | Nouveaux derives indoliques presentant des activites inhibitrices de chymase et leur procede de preparation |
AU779041B2 (en) * | 2000-05-02 | 2005-01-06 | Meiji Seika Kaisha Ltd. | Novel indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof |
US6852734B2 (en) * | 2000-05-02 | 2005-02-08 | Meiji Seika Kaisha, Ltd. | Indole derivatives exhibiting chymase-inhibitory activities and process for preparation thereof |
JP4824092B2 (ja) * | 2005-12-01 | 2011-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | 新規なビニル様酸誘導体 |
JP2010505900A (ja) * | 2006-10-13 | 2010-02-25 | エフ.ホフマン−ラ ロシュ アーゲー | キマーゼ阻害剤としてのビニル酸誘導体 |
Also Published As
Publication number | Publication date |
---|---|
EP1136488A4 (en) | 2002-06-12 |
EP1136488A1 (en) | 2001-09-26 |
AU1414000A (en) | 2000-06-19 |
US6432978B1 (en) | 2002-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994009147A1 (en) | Fo-1289 substance and its production | |
JPH06339390A (ja) | Bu−4164e−a及びb、プロリルエンドペプチダーゼインヒビター | |
WO1993000361A1 (fr) | Nouveaux inhibiteurs de propyle d'endopeptidase sna-115 et sna-115t, leur production et souche utilisee dans leur production | |
JPH06234693A (ja) | 新規イソテトラセノン系物質及びその製造法 | |
WO2000032587A1 (fr) | Substances sf2809-i, ii, iii, iv, v et vi presentant une activite d'inhibition de la chymase | |
HU202591B (en) | Process for producing antibiotic bu-3420t and pharmaceutical composition comprising such antibiotic | |
JP3111240B2 (ja) | Fa−70d物質、その製造法及びその用途 | |
Tani et al. | SF2809 compounds, novel chymase inhibitors from Dactylosporangium sp. 1. Taxonomy, fermentation, isolation and biological properties | |
RU2221870C2 (ru) | Мумбайстатин, способ его получения и его применение в качестве фармацевтического препарата | |
JPH0641067A (ja) | 新規カルパイン阻害物質kp−1241及びその製造法 | |
JP3806856B2 (ja) | A−1211物質 | |
JP3092877B2 (ja) | 新規ペプチドsna−115及びsna−115t、その製造法及び新規ペプチド産生菌株 | |
JP3687929B2 (ja) | 新規化合物a−76202及びその製造法 | |
EP0432697A2 (en) | BU-4146T antibiotic | |
JP3686693B2 (ja) | 新規生理活性物質ベラクチンaおよびbとその製造法 | |
EP0629184A1 (en) | TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS | |
JPH06339395A (ja) | 新規生理活性物質及びその製造法 | |
JP3304358B2 (ja) | ストレプトスポランギウムからのws79089物質 | |
JPH09169756A (ja) | 生理活性物質ei−1941類 | |
JPH1045789A (ja) | 新規生理活性物質na16887、その製造法およびその用途 | |
JPH0525190A (ja) | 新規薬理活性物質クリソスポリン及びその製造法 | |
JP2000086627A (ja) | 抗菌性物質be−54476及びその製造法 | |
JP2007131552A (ja) | 新規抗生物質sf2856物質、その製造法および医薬組成物 | |
JPH1017527A (ja) | 抗菌性物質be−39589類及びその製造法 | |
WO1992022562A1 (en) | Substances wb2663, production thereof and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 2000 14140 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AU BA BB BG BR CA CN CR CU CZ DM EE GD GE HR HU ID IL IN IS JP KR LC LK LR LT LV MA MG MK MN MX NO NZ PL RO SG SI SK TR TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 585229 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09857037 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999973023 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999973023 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999973023 Country of ref document: EP |